1,896 search results for “drug discovery” in the Public website
-
Drug discovery pipeline
The drug discovery pipeline is used to describe the stages in drug discovery. The earliest stage concerns with the identification of potential targets and molecules ('hits') that can modulate their function, while more advanced stages are about developing these hits into viable experimental drugs and…
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Drug Discovery & Safety
In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Computational Drug Discovery
Research in this group, headed by Gerard van Westen, focusses on computational methods integrated in different parts of the drug discovery process. More specifically, topics include innovative treatments for cancer, selectivity modeling, translational research, allosteric modulation, drug resistance…
-
Drug Discovery and Safety (MSc)
The master's specialisation Drug Discovery and Safety at Leiden University provides students with research-oriented education into the discovery of new drug targets and new lead molecules, particularly in the field of cancer, through a combination of advanced imaging techniques (‘systems microscopy’),…
-
Leiden Early Drug Discovery & Development
Despite recent advances in medicine, many devastating disorders like cancer and cardiovascular, neurodegenerative and infectious diseases still lack effective treatments. In order to address this challenge, we, as scientists from Leiden University, joined hands in the LED3 network. LED3, for Leiden…
-
LED3 Drug Discovery Case Studies
To get a feeling of how we operate at LED3 when it comes to Early Drug Discovery, please browse through our case studies. When you select a case study you’ll find relevant contacts.
-
Translational drug discovery and development
We cover the entire spectrum from target identification to the evaluation of the efficacy and safety of novel medicines in clinical practice.
-
Division of Drug Discovery & Safety
We are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Data-Driven Drug Discovery Network (D4N)
The Data-Driven Drug Discovery Network (D4N) is an initiative by researchers from Leiden University and collaborators to join efforts in applying and developing novel techniques from data science to drug discovery and related topics from bioinformatics.
-
Kinetics for drug discovery – The first step towards an improved drug discovery paradigm
Supervisor: Indira Nederpelt
-
Postdoc AI and physics based drug discovery
Science, Institute of Biology Leiden (IBL), Leiden Academic Centre for Drug Research (LACDR)
-
Cancer Drug Target Discovery
We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.
-
Cancer Drug Target Discovery
In this research group, headed by Prof. Erik Danen, the aim is to unravel cellular signaling mechanisms in normal and diseased cells, with a long-standing interest in cell adhesion signaling. In complex multicellular organisms such as ourselves, a division of labor emerges where different tissues and…
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
The Role of Target Binding Kinetics in Drug Discovery
Source: ChemMedChem (2015)
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
Scientific computing for Drug Discovery in Python and/or R
Data analysis with Python and R are rapidly becoming essential skills for modern scientists. Therefore, we are offering courses to develop your scientific computing skills. Those courses are optional for LACDR PhD candidates.
-
Activity-based protein profiling for drug discovery
Activity-based protein profiling (ABPP, also termed chemical proteomics), is one of the pillars of chemical biology, and at LED3 we have taken it to the next level. ABPP allows the assessment of protein function in live cells and tissues, which means that the activity of a complete protein family can…
-
Transforming data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Kinetics for Drug Discovery: a Case for the Adenosine A3 receptor
Supervisor: Lizi Xia
-
Discovery of metastasis promoting candidate drug targets
Discovery of metastasis promoting candidate drug targets
-
Systems microscopy-based drug target discovery in pathogen-meidated inflammatory respons signalling
Establishing human induced pluripotent stem cell (iPSC) CRISPR-Cas9-based fluorescent reporter cell lines for NF-kB signalling. We will use this to enable studying the dynamic activation and downstream signalling of Toll-like receptor and cytokine signalling in iPSC-derived differentiated cells in a…
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
Image-based phenotypic screening for breast cancer metastasis drug target discovery
The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
Rethinking drug discovery: Vidi grant for Laura Heitman
Laura Heitman has been awarded a VIDI grant for her innovative drug research. Heitman strives to optimize a drug’s binding kinetics at its target in order to ultimately fight diseases effectively. She even pleads for a paradigm shift in drug discovery.
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
PROTEOMINING: a novel proteomics-based pipeline for drug and enzyme discovery in filamentous actinomycetes
Can a new proteomics workflow be developed to link genes and gene clusters to bioactive molecules, identify novel compounds and enhance the production in the Streptomyces lividans enzyme?
-
De Witte et al publish in Nature Drug Discovery Reviews
Nature Reviews Drug Discovery volume 18, pages 82–84 (2019). The implications of target saturation for the use of drug–target residence time Wilbert de Witte, Meindert Danhof, Piet van der Graaf, and Elizabeth de Lange
-
Drug discovery 3.0: more effective and humane
Discovering effective new drugs is a long, expensive and uncertain process. Laura Heitman wants to improve this by finding out more about how drugs bind to proteins that play a role in disease. She calls it ‘drug discovery 3.0’. Inaugural lecture on 9 December.
-
Artificial intelligence as the co-pilot for drug discovery
There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…
-
Target Discovery
The goal of target discovery is to identify and validate proteins and biological pathways that are involved in the disease process. Modulating these target proteins and pathways with small molecules, therapeutic proteins or other biomolecules (e.g. mRNA) could deliver an effective and safe drug or v…
-
Novel immunomodulatory drugs for tuberculosis treatment
Can drugs that target host signaling pathways be used to eradicate antibiotic-resistant bacteria?
-
Towards improved drug action : target binding kinetics and functional efficacy at the mGlu2 receptor
During the course of drug discovery translational steps are made.
-
Alumnus Robert Ietswaart: ‘Machine learning is revolutionising drug discovery’
Robert Ietswaart does research into gene regulation at the famous Harvard Medical School in Boston. He developed an algorithm to better predict whether a candidate medicine is going to produce side effects. He studied mathematics and physics in Leiden, and gained his PhD in computational biology in…
-
Leiden Academic Centre for Drug Research
The Leiden Academic Centre for Drug Research (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development.
-
To explore the drug space smarter: Artificial intelligence in drug design for G protein-coupled receptors
Over several decades, a variety of computational methods for drug discovery have been proposed and applied in practice. With the accumulation of data and the development of machine learning methods, computational drug design methods have gradually shifted to a new paradigm, i.e. deep learning methods…
-
Systems pharmacology-based translational drug pharmacokinetics
High-throughput holistic preclinical screens are increasingly used in drug discovery, to assess both drug efficacy and drug safety.
-
Collaborative and effective drug development
There are many complex links in the chain that provides patients with new drugs: from fundamental science, to clinical tests, to production. The entire chain can be found in Leiden. Leiden University, the Leiden University Medical Center (LUMC) and the businesses at the Leiden Bio Science Park (LBSP)…
-
Leiden Academic Centre for Drug Research
Drug development is a complex process in which many parties work together. Every day, the researchers at LACDR devote their energies to developing drugs that are new, better, more efficient and easier to produce. And thus to the millions of patients who know all too well why this research in Leiden…
-
Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia
The disease acute myeloid leukemia (AML) is characterized by fast progression and low survival rates.
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Rob van Wijk discusses the role of zebrafish in drug discovery
Rob van Wijk gave an interview on the role of zebrafish in drug discovery and development, published in FIGON’s journal Medicines as a preview of LACDR’s representation at the PhD competition during the Dutch Medicines Days (DMD). The entire interview can be read below.
-
Discoveries in 2023
From nanoparticles to colliding ice planets and from biological origami to new x-ray scanner techniques: this year again, our scientists have made wonderful discoveries. From the largest numbers to the smallest molecules and from the oldest galaxies up to the latest algorithms, take a look at each institute's…
-
Discovering and developing drugs
Improving healthcare with our scientific discoveries: that is the goal of pharmaceutical research at Leiden University. And there’s a lot involved in that. Our research starts with the discovery of the effect achieved by a particular substance, and sometimes continues all the way through to the development…
-
Time is of the essence: investigating kinetic interactions between drug, endogenous neuropeptides and receptor
Promotor: A.P. IJzerman Co-promotor: L.H. Heitman
-
Chemical Biology
Chemical biology research at the Leiden Institute of Chemistry is aimed at understanding biological processes at the molecular level to strengthen the knowledge base of human health and disease. The approach to achieve this goal is a fundamental chemical one; with the aid of chemical probes biological…
-
Erik Danen appointed as Professor of Cancer drug target discovery
As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.